- Sector
- Healthcare
- Industry
- Pharmaceutical Retailers
Highlights
- Market Cap
- $6.81B
- Enterprise Value
- $5.98B
- EPS (TTM)
- CN¥3.59
- PE Ratio
- 15.87
- PEG Ratio
- 0.34
- Total Revenue (TTM)
- CN¥58.25B
- Gross Profit (TTM)
- CN¥13.93B
- EBITDA (TTM)
- CN¥3.24B
- Year Range
- $8.26 - $19.45
- ROA (TTM)
- 12.63%
- ROE (TTM)
- 16.33%
Share Price Chart
Loading charts...
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
ALBBY Performance Chart
Alibaba Health Information Technology Limited (ALBBY) is down 36.0% since the beginning of the year. At $8 per share, ALBBY is trading 56.7% below its 52-week high of $19. Investors who bought $1,000 worth of ALBBY shares 5 years ago would now be looking at an investment worth $192.
Loading charts...
Returns By Period
Alibaba Health Information Technology Limited (ALBBY) has returned -35.96% so far this year and -29.88% over the past 12 months.
Alibaba Health Information Technology Limited
- 1D
- -5.24%
- 1M
- -10.95%
- YTD
- -35.96%
- 6M
- -37.87%
- 1Y
- -29.88%
- 3Y*
- -11.57%
- 5Y*
- -28.13%
- 10Y*
- —
Benchmark (S&P 500 Index)
- 1D
- -0.37%
- 1M
- -0.01%
- YTD
- 9.16%
- 6M
- 8.64%
- 1Y
- 25.22%
- 3Y*
- 19.78%
- 5Y*
- 11.99%
- 10Y*
- 13.88%
ALBBY Monthly Returns History
Based on dividend-adjusted daily data since May 7, 2020, ALBBY's average daily return is -0.02%, while the average monthly return is -0.46%.
Historically, 41% of months were positive and 59% were negative. The best month was Nov 2022 with a return of +93.0%, while the worst month was Mar 2026 at -34.6%. The longest winning streak lasted 3 consecutive months, and the longest losing streak was 8 months.
On a daily basis, ALBBY closed higher 17% of trading days. The best single day was Dec 8, 2022 with a return of +32.0%, while the worst single day was Mar 26, 2026 at -35.2%.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 30.29% | -10.28% | -34.57% | 19.90% | -22.57% | -9.81% | -35.96% | ||||||
| 2025 | 9.06% | 34.25% | -6.54% | 2.10% | -16.52% | 20.23% | -0.57% | 5.77% | 51.27% | -18.24% | -6.78% | -11.32% | 50.77% |
| 2024 | -25.93% | 8.88% | 3.33% | -23.44% | 26.80% | -1.33% | -3.44% | -9.65% | 59.57% | -14.17% | -10.49% | -5.48% | -19.31% |
| 2023 | 7.92% | -24.91% | 1.29% | 0.00% | -12.44% | -5.28% | 17.21% | -24.11% | 16.12% | -6.32% | 4.21% | -10.96% | -38.88% |
| 2022 | -8.52% | -6.15% | -6.68% | -24.40% | 5.76% | 29.32% | -4.45% | -12.29% | -19.50% | -8.76% | 93.01% | 8.47% | 6.77% |
| 2021 | 3.96% | 10.34% | -17.14% | 5.88% | -19.07% | -7.24% | -32.08% | 7.35% | -19.90% | -5.57% | -26.51% | -11.40% | -72.88% |
Benchmark Metrics
Alibaba Health Information Technology Limited has an annualized alpha of -11.38%, beta of 0.49, and R2 of 0.01 versus S&P 500 Index. Calculated based on daily prices since May 07, 2020.
- This stock participated in 184.18% of S&P 500 Index downside but only 25.35% of its upside - more exposed to losses than it benefited from rallies.
- Beta of 0.49 may look defensive, but with R2 of 0.01 this stock is largely uncorrelated with S&P 500 Index - low beta reflects independence, not downside protection. See the Volatility section for a true picture of this stock's risk.
- R2 of 0.01 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.
- Alpha
- -11.38%
- Beta
- 0.49
- R²
- 0.01
- Upside Capture
- 25.35%
- Downside Capture
- 184.18%
Return for Risk
Risk / Return Rank
ALBBY ranks 27 for risk / return — below 27% of stocks on our site. The returns aren't fully compensating for the risk involved. This isn't necessarily a dealbreaker, but factor it into your decision — especially if you're risk-averse.
Return / Risk — by metrics
The table below present risk-adjusted performance metrics for Alibaba Health Information Technology Limited (ALBBY) and compare them to S&P 500 Index.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| ALBBY | Benchmark | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -2.38 | ||
| Sortino ratioReturn per unit of downside risk | -2.72 | ||
| Omega ratioGain probability vs. loss probability | 1.01 | 1.37 | -0.36 |
| Calmar ratioReturn relative to maximum drawdown | -0.52 | 2.78 | -3.31 |
| Martin ratioReturn relative to average drawdown | -1.09 | 12.44 | -13.53 |
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading charts...
Worst Drawdowns
The table below displays the maximum drawdowns of the Alibaba Health Information Technology Limited. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the Alibaba Health Information Technology Limited was 91.29%, occurring on Apr 15, 2024. The portfolio has not yet recovered.
The current Alibaba Health Information Technology Limited drawdown is 89.35%.
Related event | Drawdown | Fall | Recovery | Underwater |
|---|---|---|---|---|
2024 bear market2024 | -91.29%Apr 2024 | 3y 1mo | — | 5y 4moFeb 2021 - now |
2020 bear market2020 | -24.33%Sep 2020 | 8d | 3mo 1d | 3mo 9dAug 2020 - Dec 2020 |
2021 correction2021 | -12.55%Jan 2021 | 7d | 19d | 26dJan 2021 - Feb 2021 |
2021 pullback2021 | -8.39%Jan 2021 | 14d | 7d | 21dDec 2020 - Jan 2021 |
2020 pullback2020 | -2.79%Jul 2020 | 0s | 3d | 3dJul 2020 - Jul 2020 |
Drawdown Indicators
| ALBBY | Benchmark | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -91.29% | -56.78% | -34.51% |
Max Drawdown (1Y)Largest decline over 1 year | -57.53% | -9.10% | -48.43% |
Max Drawdown (3Y)Largest decline over 3 years | -57.53% | -18.90% | -38.63% |
Max Drawdown (5Y)Largest decline over 5 years | -85.08% | -25.43% | -59.65% |
Max Drawdown (10Y)Largest decline over 10 years | — | -33.92% | — |
Current DrawdownCurrent decline from peak | -89.35% | -1.80% | -87.55% |
Average DrawdownAverage peak-to-trough decline | -71.44% | -10.71% | -60.73% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 27.43% | 2.03% | +25.40% |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading charts...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of Alibaba Health Information Technology Limited over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Valuation
The Valuation section provides an overview of how Alibaba Health Information Technology Limited is priced in the market compared to other companies in the Pharmaceutical Retailers industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PE Ratio
The chart displays the Price-to-Earnings (P/E) ratio for ALBBY, comparing it with other companies in the Pharmaceutical Retailers industry. Currently, ALBBY has a P/E ratio of 15.9. This P/E ratio is significantly higher than those of industry peers. This could indicate that the stock is overvalued or that investors expect strong future growth.
PEG Ratio
The chart shows the Price/Earnings to Growth (PEG) ratio for ALBBY compared to other companies in the Pharmaceutical Retailers industry. ALBBY currently has a PEG ratio of 0.3. This PEG ratio is low compared to industry peers, which could indicate the stock is undervalued relative to its expected growth.
PS Ratio
This chart shows the Price-to-Sales (P/S) ratio for ALBBY relative to other companies in the Pharmaceutical Retailers industry. Currently, ALBBY has a P/S ratio of 0.8. This P/S ratio falls within the average range for the industry, suggesting the stock is fairly valued based on its revenue.
PB Ratio
The chart illustrates the Price-to-Book (P/B) ratio for ALBBY in comparison with other companies in the Pharmaceutical Retailers industry. Currently, ALBBY has a P/B value of 2.6. This P/B ratio is in line with the industry average, suggesting the stock is valued fairly in relation to its book value.
Income Statement
| TTM | |
|---|---|
Revenue | — |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | — |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | — |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |
Build a portfolio with ALBBY
Add Alibaba Health Information Technology Limited to a portfolio and analyze allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Analyzer with ALBBY